000124368 001__ 124368
000124368 005__ 20241125101129.0
000124368 0247_ $$2doi$$a10.3390/cancers15030871
000124368 0248_ $$2sideral$$a132865
000124368 037__ $$aART-2023-132865
000124368 041__ $$aeng
000124368 100__ $$aLaredo, V.
000124368 245__ $$aRisk of cancer in patients with inflammatory bowel diseases and keys for patient management
000124368 260__ $$c2023
000124368 5060_ $$aAccess copy available to the general public$$fUnrestricted
000124368 5203_ $$aChronic inflammation in patients with Inflammatory Bowel Disease (IBD) leads to an increased risk of colorectal cancer, small bowel cancer, intestinal lymphoma and cholangiocarcinoma. However, treatments for IBD have also been associated with an increased risk of neoplasms. Patients receiving Thiopurines (TPs) have an increased risk of hematologic malignancies, non-melanoma skin cancer, urinary tract neoplasms and cervical cancer. Anti-TNFs have been associated with a higher risk of neoplasms, mainly lymphomas and melanomas; however, the data are controversial, and some recent studies do not confirm the association. Nevertheless, other biologic agents, such as ustekinumab and vedolizumab, have not shown an increased risk of any neoplasm to date. The risk of malignancies with tofacitinib exists, but its magnitude and relationship with previous treatment with TPs is not defined, so more studies from daily clinical practice are needed. Although biologic therapy seems to be safe for patients with current cancer or a prior history of cancer, as has been demonstrated in other chronic inflammatory conditions, prospective studies in this specific population are needed. Until that time, it is crucial to manage such conditions via the combined clinical expertise of the gastroenterologist and oncologist.
000124368 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000124368 590__ $$a4.5$$b2023
000124368 592__ $$a1.391$$b2023
000124368 591__ $$aONCOLOGY$$b78 / 322 = 0.242$$c2023$$dQ1$$eT1
000124368 593__ $$aOncology$$c2023$$dQ1
000124368 593__ $$aCancer Research$$c2023$$dQ2
000124368 594__ $$a8.0$$b2023
000124368 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion
000124368 700__ $$aGarcía Mateo, S.$$uUniversidad de Zaragoza
000124368 700__ $$aMartínez Domínguez, S. J.$$uUniversidad de Zaragoza
000124368 700__ $$0(orcid)0000-0002-2945-7368$$aLópez de la Cruz, J.
000124368 700__ $$0(orcid)0000-0002-3545-2707$$aGargallo Puyuelo, C. J.$$uUniversidad de Zaragoza
000124368 700__ $$0(orcid)0000-0003-0076-3529$$aGomollón, F.$$uUniversidad de Zaragoza
000124368 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000124368 773__ $$g15, 3 (2023), 871 [18 pp.]$$pCancers$$tCancers$$x2072-6694
000124368 8564_ $$s692113$$uhttps://zaguan.unizar.es/record/124368/files/texto_completo.pdf$$yVersión publicada
000124368 8564_ $$s2649506$$uhttps://zaguan.unizar.es/record/124368/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000124368 909CO $$ooai:zaguan.unizar.es:124368$$particulos$$pdriver
000124368 951__ $$a2024-11-22-11:58:21
000124368 980__ $$aARTICLE